Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
1(20%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
20%
Ph not_applicable
1
20%
Ph phase_3
1
20%
Ph phase_1
1
20%

Phase Distribution

1

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(3)

Detailed Status

Completed3
Recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 31 (25.0%)
N/A1 (25.0%)

Trials by Status

recruiting120%
completed360%
not_yet_recruiting120%

Recent Activity

1 active trials
Showing 5 of 5
not_yet_recruiting

A Real World Study of Polyene Phosphatidylcholine Injection for the Prevention and Treatment of DILI in Patients With Malignant Hematological Diseases

NCT07476885
completedphase_1

Evaluate Pharmacokinetic/Pharmacodynamic and Safety/Tolerability of AYP-101 in Healthy Subjects

NCT05476094
completedphase_3

Evaluate the Efficacy and Safety of AYP-101 for the Reduction of Submental Fat in Chin Area

NCT06256445
recruitingnot_applicable

Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia

NCT06922669
completedphase_2

Determine the Dosing Interval and Optimal Dose of AYP-101 for the Reduction of Submental Fat in Chin Area

NCT05266729

Clinical Trials (5)

Showing 5 of 5 trials
NCT07476885

A Real World Study of Polyene Phosphatidylcholine Injection for the Prevention and Treatment of DILI in Patients With Malignant Hematological Diseases

Not Yet Recruiting
NCT05476094Phase 1

Evaluate Pharmacokinetic/Pharmacodynamic and Safety/Tolerability of AYP-101 in Healthy Subjects

Completed
NCT06256445Phase 3

Evaluate the Efficacy and Safety of AYP-101 for the Reduction of Submental Fat in Chin Area

Completed
NCT06922669Not Applicable

Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia

Recruiting
NCT05266729Phase 2

Determine the Dosing Interval and Optimal Dose of AYP-101 for the Reduction of Submental Fat in Chin Area

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5